Clinical trial NCT04245696: Bipolar RF Microneedling for Improved Laxity and Lift of the Submental and Neck Tissue and Effect on Elastin
Official title: Clinical Assessment of Bipolar Radiofrequency Microneedling for Improved Laxity and Lift of the Submental and Neck Tissue
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Skin Laxity
Keywords: RF
Micro-needling
Submental Skin Laxity
Lead sponsor: Candela Corporation
Sponsor class: INDUSTRY
First posted: 2020-01-29
Enrollment: 0
Sex: ALL
Minimum age (years): 21
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is being conducted to evaluate the safety and efficacy of bipolar fractional radiofrequency treatment via use of the Profound System to achieve lift in lax submental (beneath the chin) and neck tissue

Detailed description: A multi-center, blinded, non-randomized, non-controlled study

Up to 60 eligible participants will be enrolled at up to three (3) sites. Participants will receive one (1) treatment in the submental/neck area. Participants will complete follow-up visits for clinical evaluation at Day 14, 1 Month, 3 Month, and 6 Months after the study treatment. Standard photography will be obtained at Screening to the 6 Month follow-up, and 3D photography will be obtained at Screening, Month 3, and Month 6 visit.

Eligibility criteria: Inclusion Criteria:

* Healthy male and female adults between ages 21-70 years of age.
* Desire skin laxity lift of submental and neck regions.
* Confirmed BMI ≤ 35.
* Subjects who can read, understand, and sign the Informed Consent Form.
* Subjects willing and able to comply with all study requirements.
* Fitzpatrick skin type I-VI.
* Submental fat graded by the Investigator as ≥ 1 using the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS, 0=Absent (No localized submental fat evidence), 4=Extreme (Extreme submental convexity)

Exclusion Criteria:

* Active localized or systemic infections, that may alter wound healing.
* Immunocompromised subjects.
* Subjects with coagulation disorder.
* History of skin photosensitivity disorders, or use of photosensitizing drugs (e.g., tetracycline or sulfa drugs).
* Pregnant and/or lactating (All female volunteers will be advised about using birth control during the period of study).
* Excessive skin laxity on the submental and neck (Submental Skin Laxity Grade: SMSLG 4=Severe, superficial wrinkling present), or other anatomical feature for which reduction in submental fat (SMF) which may, in the judgment of the investigator, result in an aesthetically unacceptable outcome.
* Scarring in areas to be treated.
* Tattoos in the treatment areas to be treated.
* Significant open facial wounds or lesions.
* Severe or cystic acne in treatment areas.
* Current active smoker.
* Use of Accutane (Isotretinoin) within the past 6 months.
* Use of topical retinoids within 48 hours.
* Use of prescription anticoagulants.
* Pacemaker or internal defibrillator.
* History of skin disorders resulting in abnormal wound healing (i.e. keloids, extreme dry and fragile skin).
* Subjects on current oral corticosteroid therapy or within the past 6 months
* Metal implants in the treatment area.
* In the opinion of the investigator, subject is unwilling or unable to adhere to all study requirements, including application and follow-up visits.
* Subjects with a history of radiation therapy to the treatment area.
* Subject has a history of allergy to lidocaine or ester-based local anesthetics.
* Subjects with significant cardiac history or rhythm disturbance who may be unable to tolerate lidocaine with epinephrine.
* Subjects with any skin pathology or condition in the treatment area that could interfere with evaluation or with the use of typical ancillary medical treatments or care used before, during or after treatments (e.g. psoriasis, rosacea, eczema, seborrheic dermatitis, vitiligo, hyper or hypo-skin pigmentation conditions such as post inflammatory hyperpigmentation).
* Subjects who are unwilling to shave excessive hair in the treatment area that might influence or impair evaluation in the opinion of the Investigator.
* Subjects have undergone skin resurfacing or tightening treatments in the treatment area over the past year.
* Subjects have undergone dermatological treatments such as fillers and neurotoxins for the past 6 months in the treatment area.
* Subjects have undergone laser and light treatments in the treatment area over the past 3 months.
* Subjects have undergone superficial peel or microdermabrasion within 4 weeks.

Primary outcomes:
measure: Change in submental skin laxity
timeFrame: Baseline - Day 180 (6 months post-treatment)
measure: Occurrence, severity, and relatedness of adverse events
timeFrame: Baseline - Day 180 (6 months post-treatment)
Secondary outcomes:
measure: Change in submental skin laxity
timeFrame: Baseline - Day 90 (3 months post-treatment)
measure: Surface Area Assessment to demonstrate percentage of participants having improvement in tissue lift (> 20mm2 in submental and neck skin laxity)
timeFrame: Baseline vs. Day 180
measure: Subject assessment of improvement in skin laxity
timeFrame: 3 Month Follow-Up and 6 Month Follow-Up
measure: Subject satisfaction of treatment results: Subject Satisfaction scale
timeFrame: Day 14 - 6 Month Follow-Up
measure: Subject assessment of pain: Numerical Pain Rating Scale
timeFrame: Treatment Visit
Other outcomes:
Locations:
city: Marlborough
country: United States
facility: Candela Institute of Excellence
state: Massachusetts
Study officials:
affiliation: Candela Medical
name: Konika Patel Schallen, MD
role: PRINCIPAL_INVESTIGATOR
References: